AbbVie Inc.

- AbbVie is anticipating adjusted net interest expense of approximately $2 billion in 2024, which reflects financing the ImmunoGen and Cerevel transactions. - There is mention of dilution related to the recently closed acquisition of ImmunoGen and the pending acquisition of Cerevel, with an EPS impact of $0.42. - No explicit statements were made about new fundraising through debt or equity in the near future. - The company emphasizes managing its financial outlook with recent acquisitions but does not indicate plans for additional fundraising rounds via debt or equity beyond current transactions.

- AbbVie completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening the oncology pipeline. - Integration of ImmunoGen into AbbVie has been seamless, indicating strategic investment in oncology capabilities. - AbbVie is on track to close the pending acquisition of Cerevel Therapeutics by mid-year, which will further augment their neuroscience portfolio. - Continued investment in research and development with a focus on novel early-stage programs and partnerships in oncology and immunology. - Investments include expanding aesthetics business, evidenced by the U.S. approval of Juvederm Voluma XC for temple hollows. - Commitment to supporting long-term growth through diversified portfolio and robust pipeline with new product launches (e.g., Skyrizi in ulcerative colitis). - Guidance raised reflecting strong performance and ongoing strategic investments aimed at revenue growth and market expansion.

- AbbVie expects robust revenue growth in 2025 and accelerating growth in 2026 and beyond, driven by expanding margins and a diversified portfolio (Page 6). - Ex-Humira growth platform delivered over 15% revenue growth in Q1 2024, with key products showing double-digit growth contributing to strong top and bottom-line results (Page 1). - Skyrizi showed exceptional momentum with operational growth of 48%, gaining significant market share in psoriasis and IBD (Page 1). - The aesthetics business in China faces near-term economic headwinds with expected negative market growth until recovery in the second half of 2024; investments will continue to support growth post-recovery (Page 8). - AbbVie is confident of favorable access and strong contracting for Skyrizi and Rinvoq in 2025 and beyond, supporting continued sales growth (Page 6). - Biosimilar competition impacts Humira volume mostly within first weeks post-loss of exclusivity, but volume erosion is generally in line with expectations, with a positive tail expected for Humira sales in the U.S. (Page 6).

- Robust revenue growth expected in 2025, accelerating further in 2026 and beyond (Rob Michael, COO). - Operating margin is expected to expand, typically leading to earnings growth outpacing revenue growth. - Exception in 2025: net interest expense will affect usual earnings acceleration but still delivering solid earnings growth. - AbbVie raised adjusted EPS guidance for 2024 to between $11.13 and $11.33, up by $0.16 due to strong Q1 results. - Growth driven by a diversified portfolio, including strong performance from Skyrizi, Venclexta, Vraylar, and others. - Continued robust ex-Humira growth platform supports long-term outlook. - Overall, AbbVie anticipates a high-single-digit revenue compound annual growth rate (CAGR) through the end of the decade.

- The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders. - However, there are mentions of contracting and sales dynamics: - Humira contracting season typically starts April or May, with efforts towards multi-year contracts and stable pricing. - Skyrizi is expected to have very favorable access in 2025 and beyond. - In aesthetics, inventory held by customers was reduced by about $50 million in Q1 but expected to recover in Q2. - Elahere had approximately $110 million in sales for the full quarter after close. - Overall, the company expects stable market positions with ongoing contract negotiations and cautious optimism about sales recovery and growth in certain segments such as biosimilars and aesthetics.